AU2211100A - Therapeutic applications of flint polypeptides - Google Patents

Therapeutic applications of flint polypeptides

Info

Publication number
AU2211100A
AU2211100A AU22111/00A AU2211100A AU2211100A AU 2211100 A AU2211100 A AU 2211100A AU 22111/00 A AU22111/00 A AU 22111/00A AU 2211100 A AU2211100 A AU 2211100A AU 2211100 A AU2211100 A AU 2211100A
Authority
AU
Australia
Prior art keywords
therapeutic applications
flint polypeptides
flint
polypeptides
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22111/00A
Other languages
English (en)
Inventor
Fredric Jay Cohen
James Arthur Posada
Daniel Wierda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/006797 external-priority patent/WO1999050413A2/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2211100A publication Critical patent/AU2211100A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU22111/00A 1998-12-22 1999-12-21 Therapeutic applications of flint polypeptides Abandoned AU2211100A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11340798P 1998-12-22 1998-12-22
US60113407 1998-12-22
PCT/US1999/006797 WO1999050413A2 (en) 1998-03-30 1999-03-30 THERAPEUTIC APPLICATIONS OF MATURE FLINT (mFLINT) POLYPEPTIDES OR OPG3, A MEMBER OF THE TNF RECEPTOR SUPERFAMILY
WOUS9906797 1999-03-30
US17223999P 1999-10-20 1999-10-20
US60172239 1999-10-20
PCT/US1999/030734 WO2000037094A2 (en) 1998-12-22 1999-12-21 Therapeutic applications of flint polypeptides

Publications (1)

Publication Number Publication Date
AU2211100A true AU2211100A (en) 2000-07-12

Family

ID=27378725

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22111/00A Abandoned AU2211100A (en) 1998-12-22 1999-12-21 Therapeutic applications of flint polypeptides

Country Status (5)

Country Link
EP (1) EP1140138A2 (ja)
JP (1) JP2003520761A (ja)
AU (1) AU2211100A (ja)
CA (1) CA2358508A1 (ja)
WO (1) WO2000037094A2 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000070174A (ko) 1997-01-14 2000-11-25 벤슨 로버트 에이치. 종양 괴사 인자 수용체 6α 및 6β
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
AU2001280460A1 (en) * 2000-08-02 2002-02-13 Eli Lilly And Company Pulmonary administration of flint
GB202016058D0 (en) * 2020-10-09 2020-11-25 Ucl Business Ltd Therapeautic treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000070174A (ko) * 1997-01-14 2000-11-25 벤슨 로버트 에이치. 종양 괴사 인자 수용체 6α 및 6β
US5885800A (en) * 1997-02-04 1999-03-23 Smithkline Beecham Corporation DNA encoding tumor necrosis related receptor, TR4
WO1999004001A1 (en) * 1997-07-21 1999-01-28 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-5
CA2299619A1 (en) * 1997-08-06 1999-02-18 Regeneron Pharmaceuticals, Inc. Human orphan receptor ntr-1
AU762959B2 (en) * 1997-09-18 2003-07-10 Genentech Inc. DcR3 polypeptide, A TNFR homolog
WO1999026977A1 (en) * 1997-11-24 1999-06-03 Biogen, Inc. Novel receptors opg-2
KR20010042364A (ko) * 1998-03-30 2001-05-25 피터 지. 스트링거 성숙 ＦＬＩＮＴ(ｍＦＬＩＮＴ) 폴리펩타이드 또는 ＴＮＦ수용체인 ＯＰＧ3의 치료학적 용도

Also Published As

Publication number Publication date
WO2000037094A2 (en) 2000-06-29
JP2003520761A (ja) 2003-07-08
EP1140138A2 (en) 2001-10-10
CA2358508A1 (en) 2000-06-29
WO2000037094A3 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
AU6241698A (en) Tace-like and matrilysin-like polypeptides
AU5893696A (en) Modification of polypeptides
AU6513298A (en) Therapeutic compositions
AU8571198A (en) Interleukin-20
AU5893796A (en) Modification of polypeptides
AU2091799A (en) Uses of alpha-conotoxin peptides
AU7290898A (en) Preparation of fagopyritols and uses therefor
AU6303898A (en) Component of bromelain
AU3568900A (en) Interactions of ku polypeptides and applications thereof
AU2211100A (en) Therapeutic applications of flint polypeptides
AU2241699A (en) Expression of proteolytically-sensitive peptides
AU8337298A (en) Ceramic composite body
AUPP091197A0 (en) Direct manipulation of compressed geometry
AU1189101A (en) Therapeutic applications of flint polypeptides
AU4629399A (en) Substituted piperazones and their therapeutic uses
AU8102498A (en) Preparation of diaryl-benzopyrans
AU7641098A (en) Therapeutic composition
EP1144629A3 (en) Further pro polypeptides and sequences thereof
AUPQ645700A0 (en) Novel polypeptides and polynucleotides and methods of using them
AU1426595A (en) Ceramic warmer
AU2001277750A1 (en) Use of polypeptide
AU5005099A (en) Benzoquinolizidine and benzoindolizidine derivatives and therapeutic uses thereof
AU6692298A (en) New applications of gene therapy technology
AU5725899A (en) Applications of protective ceramics
AU9457498A (en) Electro conductive ceramic composition

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase